Podcasts about Cart

In this week's episode, we'll learn about using AI to assess transplant risk in myelofibrosis. In a step toward personalized medicine, researchers report on a machine learning model that identifies 25% of patients with poor outcomes. After that: preventing priapism in men with sickle cell anemia. A recent phase 2 feasibility study shows high rates of recruitment, retention, and adherence to oral therapies, coupled with a significant reduction in the risk of this difficult complication. Finally, new research indicates that hallmarks of terminal T-cell exhaustion are absent in multiple myeloma, from diagnosis through maintenance therapy. We explore these provocative and counterintuitive findings arising from profiling of blood and marrow samples.Featured Articles:Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisA controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafilHallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy

CooperationThe big go-cart race is coming up. But without teamwork, The Club discovers just how hard it is to be on the winning team. To support this ministry financially, visit: https://www.oneplace.com/donate/198/29

In the second installment of this two-part series, Dr. Jeff Ratliff and Dr. Brin E. Freund discuss clinical guidance for managing patients who may experience neurotoxicity from CAR T-cell, with a specific focus on seizure risk.  Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000213535 

Amy was surprised to find a miscellaneous item in her cart after she walked away from it to start her car in the parking lot.

Les footballeurs parlent aux footballeurs ! « Rothen s'enflamme », le rendez-vous des passionnés du ballon rond revient pour une deuxième saison !

Les footballeurs parlent aux footballeurs ! « Rothen s'enflamme », le rendez-vous des passionnés du ballon rond revient pour une deuxième saison !

Eric Ruderman, MD, leads a Northwestern Medicine panel discussion with Irene Blanco, MD, Anisha Dua, MD, and Carrie Richardson, MD. Together, they dive into the latest advances in clinical trials and treatment strategies for scleroderma, vasculitis and lupus.The panel discusses the goals and complexities of contemporary clinical trials, recent breakthroughs in therapies and the innovative potential of CAR-T therapy for managing autoimmune diseases. They emphasize the significance of personalized medicine and the collaboration needed among clinicians, industry collaborators and patient advocacy groups to drive research forward.

This week, the gals invite Irish icon Katie Charlwood of Who Did What Now Podcast to chat about the dangers of piracy (and also toddlers), some sticky handrails, a horrible hookup, brownie temptation, a coffin catastrophe, and a long-winded obit from one very lucky man. Tune in for June's Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.

In this week's episode, we'll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identification of an eight-protein risk signature as well as a novel single protein biomarker, soluble oncostatin M receptor, for risk stratification in AML.Featured Articles:Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiacMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pretransplant ConditioningBlood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

I'm CT…  When I'm not busy being Arroe the podcaster, I live in the real world.  Everybody has to have a job.  Mine is C.S.  Customer Service.  Solutions, relationships while keeping my team motivated to keep a constant connection with each guest who's chosen to stop their day to visit our location.  Episode 181 The team Isn't jelling, big super clean and locking cart syndrome This is C.T.C.S.Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-unplugged-totally-uncut--994165/support.

This week we revisit an episode that made it out of the groupchat. Besties of the pod Casey Wilson and Danielle Schneider of Bitch Sesh join the Aunties to catch up. First, SuChin regales them with tales of laser treatments in South Korea, which means they’ll be adding to cart some plane tickets soon. Then, Danielle shares an inspiring book and Casey is swayed by a 24-year-old beauty influencer. We’re all about the yin and yang here. We want to hear from you! Drop us a message on Speakpipe. Subscribe to the Add to Cart newsletter for juicy extras. Please note, Add To Cart contains mature themes and may not be appropriate for all listeners. To see all products mentioned in this episode, head to @addtocartpod on Instagram. To purchase any of the products, see below. Shoutout to Casey’s derm, Dr. Jennifer Segal of Metropolitan Dermatology Institute The Island of Sea Women by Lisa See is a beautiful story about female divers in Korea The Last of the Sea Women documentary dives into this as well The Alastin Skincare’s TransFORM Body Treatment with TriHex Technology is high value for high price point You can’t go wrong with the trusty Avené Cicalfate+ Restorative Protective Cream The Westman Atelier Vital Skincare Complexion Drops are the perfect no-makeup makeup base Jones Road is always a winner Add to Queue: Outer Banks Casey was influenced by Olivia Chatfield to get the Charlotte Tilbury Hollywood Contour Wand The Mid-Day Squares are a real treat Protect your skin from “car sun” with these window shades Love Casey and Danielle? Join Garbage World! Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia. Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium. Click this link for a list of current sponsors and discount codes for this show and all Lemonada shows: lemonadamedia.com/sponsorsSee omnystudio.com/listener for privacy information.

In part one of this two-part series, Dr. Jeff Ratliff and Dr. Brin E. Freund discuss the incidence of acute symptomatic seizures during CAR T-cell therapy.  Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000213535   

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

Ken and Anthony tell you the three worst words you can hear in the summer and talk through Lima abandoning the game.

The three worst words of summer: Cart path only+Mary Kay Cabot: Shedeur speeding is not a great look in midst of 4-way QB battle+What's the best path at QB to ensure Stefanski, Berry keep their jobs?

Dr. Jeff Ratliff talks with Dr. Brin E. Freund about the evaluated incidence and risk factors for acute symptomatic seizures during CAR T-cell therapy. Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

In today's episode, we had the pleasure of speaking with Alexey Danilov, MD, PhD, about current challenges and emerging treatment approaches for the management of leukemia and lymphoma that were published in a manuscript based on proceedings from the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. In our exclusive interview, Dr Danilov highlighted recent advances and controversies in the treatment of select patients with hematologic malignancies. He noted chemotherapy-free regimens that are shifting treatment paradigms in mantle cell lymphoma, preferred and emerging BTK inhibitors for the management of chronic lymphocytic leukemia, and the evolution of CD19-directed CAR T-cell therapies for diffuse large B-cell lymphoma. Dr Danilov concluded by taking a forward glance at future developments like BTK degraders and novel CAR T-cell therapy targets.

Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma.See the full review series on high risk lymphoma in volume 144, issue 25 of Blood.

In this episode of The Influence Factor, Alessandro Bogliari chats with Alanah Joseph, Head of Creator Partnerships at HubSpot. Alanah shares how creator partnerships are evolving, why community is key in podcasting, and strategies to grow and monetize a podcast. From networking and consistent publishing to leveraging newsletters, she offers practical insights for creators and brands alike.

Send us a textThis episode we sit down with Dr. Akhavan, Physician Scientist at The University of Kansas Cancer Center, to dive deep into the promising world of CAR T-cell therapy. Dr. Akhavan breaks down how this innovative treatment is being applied in the brain cancer space, what patients and families need to understand about its potential and limitations, and why quality of life remains a critical part of the conversation. Whether you're newly navigating a diagnosis or seeking new hope in treatment options, this episode is packed with valuable insight, empathy, and education.Support the showRare Enough is a podcast powered by Head for the Cure, sharing real stories of resilience, hope, and community from those facing brain tumors and the people who walk beside them. Subscribe, listen, and share, because every story matters, and no one should face brain cancer alone. Follow on Instagram @RareEnoughPodcast Learn more at BrainsfortheCure.org

If you're not backing us yet, head on over to our Patreon. A contribution of at least $5 a month will[...]

One of my clients just had a $63,000 launch with an almost 9% conversion rate - but honestly? The money is the least exciting part of this story. What she really achieved was proving to her nervous system that success doesn't require chaos. I work with a lot of women who have been responsible for others from a young age - incredible problem-solvers who thrive in chaos. In business, this often translates to overcomplicating everything because complexity feels safer than simplicity. But what happened when we focused her entire launch strategy on ONE thing - her waitlist - changed everything. In this episode, I'm breaking down exactly how this waitlist strategy works, why 85% of her sales came from focused effort, and the nervous system breakthrough that was more valuable than any dollar amount.In this episode, I share:

The microbiome is emerging as a key player in the effectiveness of CAR-T therapy, and today, Dr. Melody Smith, Assistant Professor of Medicine at Stanford University, sheds light on this fascinating intersection. Join us as we explore how advancements in CAR T-cell therapy are reshaping patient demographics and treatment approaches. Dr. Smith will discuss the implications of genetic engineering techniques like CRISPR, the importance of a multidisciplinary treatment strategy, and the role of antibiotic stewardship in optimizing outcomes. With insights into innovative therapies and ongoing clinical trials, this conversation promises to deepen your understanding of CAR-T therapy and its complexities, offering a glimpse into the future of cancer treatment. Read Transcription CME Information: https://stanford.cloud-cme.com/medcastepisode107 Claim CE: https://stanford.cloud-cme.com/Form.aspx?FormID=3392

An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.CancerNetwork®, in collaboration with The American Societyfor Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University HealthStephenson Cancer Center and serves as an ambassador for ASCO.The group highlighted several late-breaking abstracts,plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following:Phase 1b/2 CARTITUDE-1 trial (NCT03548207,NCT05201781)1Long-term follow-up showed that approximately one-third(33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti). An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas.With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-notevaluable [NE]). Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use2Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma.Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings.Phase 1b/2 NEXICART-2 trial (NCT06097832)3Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options.Among 12 patients who received the agent at 450x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively. With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred.References1.     Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.75072.     Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-celllymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.70233.     Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508.doi:10.1200/JCO.2025.43.16_suppl.7508

A Cirrus with fluctuating fuel flow, de-injecting an engine, and fear of overhaul are on tap for this episode. Email podcasts@aopa.org for a chance to get on the show. Join the world's largest aviation community at aopa.org/join Full notes below: Joe has a Maule with a 540 engine in it. The company has a mod to turn the engine to a carbureted version and he's wondering about the legality of something like that. Paul said it happens in the 210 market. Whether it's a good idea is another issue, the hosts say. Joe is unable to run autofuel is the injected version, which is why he's interested in it. Colleen said she'd rather have an injected engine than run mogas.   David wonders how perspective owners are so afraid of TBO. He has a 182 with an engine that's nearly at TBO, and people who contact him are afraid of the high time. The hosts discuss strategies for buyers who may be looking at airplanes with engines at TBO. Assuming the engine is running well, a new owner can fly it on that “borrowed time” while they learn and enjoy the airplane. Alternatively, if the engine truly needs to be overhauled, the time down is obviously a concern for a new owner. Mike said he thinks it's best to buy an airplane with a run-out engine. The price has been discounted for the cost of the engine, the seller is motivated, and worst case you have to overhaul it soon. And every hour and year that you don't have to overhaul it is “free.” And when it does come time to do the overhaul, you get to do it to your spec.   Shalom has a Cirrus that isn't behaving. If he sets the mixture at lean of peak, the fuel flows start to fluctuate. A few minutes later, it will drop off sharply, and then back quickly. The manifold pressure and rpm stay pretty consistent. He's changed the fuel pump and the spider. Nothing has helped. Mike said if there's a constriction in the fuel line between the fuel control unit and the manifold, it can cause oscillating fuel flow and lower flows.

Broadcast from KSQD, Santa Cruz on 6-12-2025: Dr. Dawn opens with alarming news about NIH budget cuts devastating cancer research just as breakthrough CAR-T cell therapy shows promise for gastrointestinal cancers. This personalized immunotherapy extracts patients' T cells, engineers them to target specific cancer antigens, and makes them essentially immortal before reinfusion. While previously successful only for blood cancers like leukemia and lymphoma, researchers achieved tumor shrinkage in 25% of solid GI tumor patients. However, devastating layoffs forced removal of two patients from trials due to staff shortages and supply chain disruptions. Dr. Dawn emphasizes how pregnancy can worsen hidden cancers due to immune suppression, explaining why aggressive metastasized cancers often appear shortly after childbirth. Dr. Dawn takes a call from Bob about concerning forehead growths his dermatologist examined. She speculates they're likely seborrheic keratoses - benign, stuck-on appearing growths common in sun-exposed areas that look like crumpled brown paper "spit-wads". These aging-related changes are harmless and can even be picked off, though she warns against repeatedly traumatizing any skin area as this increases cancer risk through accumulated DNA damage. She explains how repetitive trauma in occupational settings creates statistically higher cancer risks, comparing it to filling a bingo card of cellular errors. She addresses an email about Joe Tippens' cancer cure protocol involving fenbendazole, an anti-parasitic drug. Dr. Dawn explains this viral social media phenomenon began when Tippens claimed his lung cancer was cured by fenbendazole, but he was simultaneously receiving Keytruda immunotherapy at MD Anderson. The story spread rapidly in South Korea, causing pharmacy shortages. Unvalidated internet health information can spread dangerously. Dr. Dawn compares it to old-fashioned medicine show scams. trend Dr. Dawn warns about a recent vitamin B6 toxicity misdiagnosis trend affecting her patients who were told they had dangerous levels of B6 despite lacking neuropathy symptoms. Accuracy requires fasting 12 hours before blood draws, otherwise creating false elevations from recent vitamin consumption. More critically, she alerts listeners about biotin(Vitamin B7) interference with laboratory tests using biotin-streptavidin techniques. High-dose biotin supplements are often used in hair and nail health growth formulas. This can falsely alter tests for thyroid hormones, vitamin D, sex hormones, cortisol and dangerously, troponin levels that diagnose heart attacks. This could lead to missed myocardial infarctions in emergency rooms, potentially causing fatal outcomes. Dr. Dawn takes a call from Richard seeking information about a previous radio program guest. She guides him to use on-line resources at ksqd.org to find program details, pivoting into praise for libraries as community centers offering far more than internet access. She emphasizes libraries provide serendipitous discovery that algorithms can't match, encouraging people to explore their local library systems for events, historical collections, and personal assistance from knowledgeable librarians eager to help visitors navigate both physical and digital resources. She discusses the concerning trend of giving melatonin to children, calling it "the Grinch that stole children's bedtime." While used prescription-only for severe developmental disorders in Denmark and EU countries, American children receive melatonin gummies regularly, with one in five preteens using it occasionally. Dr. Dawn explains melatonin is a hormone affecting pancreas, heart, fat tissue, and reproductive organs still developing in children. Supplemental doses create blood levels 10 times higher than natural peaks, representing an uncontrolled medical experiment on developing brains and bodies. Poison control calls for melatonin ingestion increased 530% between 2012-2021, with one tragic case involving a three-month-old death where 20 melatonin bottles were found in the home. Dr. Dawn concludes by debunking food expiration date myths, explaining that Americans waste a third of food ($7 billion annually) due to misunderstanding labels. Most shelf-stable foods simply degrade in quality rather than becoming dangerous after printed dates. She notes acidic dairy products like yogurt resist bacterial contamination due to protective bacteria,and even surface mold can be scraped off safely. However, she emphasizes trusting expiration dates on lunch meats and deli products, which pose real listeria risks when stored improperly. California will soon simplify labeling laws to reduce confusion between quality and safety dates.

We start off with some good old spaceweather news, which leads into a discussion of the Earth's rapidly weakening magnetic field and the possibility of a polarity flip. We then move on to some discussion of further observations on the construction of pyramids and new things we learned in our recent trip in Egypt.In the second half of the show, we talk about the amazing cart ruts we visited in the Phrygian Valley in Turkey. We show lots of pictures and video, and discuss and discard multiple hypotheses on what they are and how they were formed.Join us, Ben from UnchartedX, Adam Young, and Karoly Poka for an afternoon at The Metropolitan Museum of Art in New York where we will peruse their collection of Ancient Egyptian artifacts, then we will move to the Explorer's Club for dinner and presentations from us and Ben!https://eveningattheexplorersclub.eventbrite.com/Join our Patreon, support the show, get extra content and early access!https://www.patreon.com/brothersoftheserpentSupport the show with a paypal donation:https://paypal.me/snakebros

In today's episode of Inside Kingston we talk about the updates on shelter services in the city, Robert Bruce Memorial Parking Garage Public Art, a preview of the upcoming council meeting, pride month, a change in the LaSalle Causeway lift schedule, an update on cart-based waste collection and an upcoming Giveaway day. You can learn more about everything mentioned in this week's episode here: ✨Shelter services - https://getinvolved.cityofkingston.ca... ✨Public art - https://getinvolved.cityofkingston.ca... ✨City Council meetings - https://www.cityofkingston.ca/council... ✨Pride - https://www.visitkingston.ca/your-gui... ✨LaSalle Causeway Lift - https://www.canada.ca/en/public-servi... ✨Cart-based Waste Collection - https://www.cityofkingston.ca/garbage... ✨Giveaway day - https://www.cityofkingston.ca/news/po...

Drs. Lipsky and Allan discuss the emerging role of immunotherapy in the management of patients with CLL, including CAR T-cell therapy and bispecific antibodies.

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-controlled trial, treatment produced rapid and durable platelet responses, with acceptable safety, in adults with immune thrombocytopenia who had failed multiple previous therapies. Finally: exploring pre-TCR surface expression patterns in T-cell ALL. Co-inhibition of the interleukin-7 receptor and pre-T cell receptor pathways may play a therapeutic role for a subset of T-lymphoblastic leukemias.Featured Articles: Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHDSafety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 studySurface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

Uma Borate, MBBS, MS, The Ohio State University, Cleveland, OH Recorded on May 27, 2025 Uma Borate, MBBS, MS Associate Professor, Division of Hematology Acute Leukemia Clinical Research Disease Group Leader The Ohio State University Cleveland, OH What's changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don't miss this dynamic conversation packed with expertise and hope for the future of AML!

Pole Vault U. Don't take that nap. State of Beverages report. Soda stats. Moving sidewalks might be on the way out. High school experiences. Jokes with Sean. Bacon news. Winner! Trademark wars. Pizza Vodka. Bar tabs.

This week Shauna and Dan try not to upset the apple cart. Bonus: The USA's earliest pen pals, wizardly cats, and Gudrun Lauret's disruptive creators (or possibly creative disruptors) It's free to join our Patreon, patreon.com/bunnytrailspod On our Patreon you have direct access to reach Shauna and Dan, plus join our weekly chats and polls. Paid tiers have even more perks, like early access and name recognition on the show. So join us on Patreon! patreon.com/bunnytrailspod Shownotes are always available on our website, bunnytrailspod.com Copyright 2025 by The Readiness Corner, LLC - All Rights Reserved  

In this episode of Careers in Discovery, we're joined by Markus Gruell, Senior Vice President of Corporate Quality at Autolus, one of the UK's leading CAR-T therapy pioneers. Markus takes us behind the scenes of Autolus' journey from a UCL spinout to a commercial-stage Biopharma company, offering a rare look at how quality underpins every part of the drug development lifecycle. From working across GMP and GCP to collaborating with regulators on novel therapies, Markus shares what it means to lead quality in a fast-moving, high-growth Biotech business. We also explore Markus' personal journey - from pharmacist to QP, and from the NHS to senior leadership - guided by a passion for learning, a commitment to patient safety, and a belief in empowering his team through empathy and integrity. If you're curious about CAR-T, what quality looks like in a next-gen therapy company, or how to build a meaningful leadership career without a traditional plan, this episode is not to be missed.  

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down with Dr. David Akhavan, a physician-scientist pioneering cell therapy research for brain cancer. Dr. Akhavan discusses the revolutionary potential of chimeric antigen receptor (CAR) T-cell therapy in treating cancers like glioblastoma, the complexities involved and the innovative approaches his team is employing, such as smarter engineered T-cells and nanoparticles. Highlighting the collaboration within KU Cancer Center, Dr. Akhavan also shares personal insights into his motivation and the future of cancer treatment. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about cell therapy at KU Cancer Center Learn more about brain cancer Read more about Dr. Akhavan's work on the KU Cancer Center blog, “Exploring Immunotherapy Treatments to Treat Brain Cancer” Learn about Head for the Cure Read how physician-scientists at KU Cancer Center bridge the gap between the laboratory and the clinic  

Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo#asco2025Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this hilarious and unfiltered episode, Donna and Brittney Boo are joined by returning guest and cart cutie Nathalie for a deep dive into the wild world of the beverage cart. It's time for confessions, cocktails, and the colorful cast of characters they encounter every week on the course.Brought to you by our favorite beverage cart experts (and cuties), Brittney Boo & Nathalie, this episode covers:*The wildest moments from the Kachina Men's Invitational at Alta Mesa*Best customer of the week, worst attitude, and a few touching moments of kindness*The top 3 most-ordered drinks right now*Donna's new favorite summer cocktail*What your drink says about your golf game (you'll either laugh—or feel very seen)*Cart-side fashion breakdowns: who's nailing the look, who's missing the mark, and a few surprises that somehow worked*A quick tip from Donna on how to balance style and function on the courseThe players who show up to slay, not score—and why we love them for itWe wrap up with Cart Confessionals (yes, they're juicy!) and break down the formats from the Alta Mesa Member-Guest: scrambles, best balls, Calcutta, horse race, and the classic ham and egg strategy.This episode is all fun, flavor, and fairway chaos—a true look into the day in the life of the beverage cart crew.Big thanks to our amazing listeners—old and new—for tuning in!Please keep sharing Golf Party Live with your golf girlfriends (and guy friends too).And we'd love to hear from you—what's your go-to cocktail on the course or at the 19th hole? Drop us a message or tag us in your favorite drink pics!

In this episode, Heather and Matthew welcome Dr. Leonardo Ferreira, Assistant Professor at the Medical University of South Carolina and cofounder of Torpedo Bio. Leo shares how his team at Torpedo Bio  is working to develop safe and effective cellular immunotherapy for solid tumors. We have an exciting conversation on the promise of CAR-T therapy, the challenges life sciences startups face, and how federal research funding impacts innovation. Tune in to hear how Torpedo Bio is pushing the boundaries of cancer treatment!

In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, involving 583 episodes of progression, found that simultaneous confirmation of disease progression using two different markers (e.g., serum protein electrophoresis and serum free light chain assay) was 98% accurate, compared to 82% for sequential confirmation. This suggests that simultaneous confirmation could improve clinical trial accuracy and reduce false censoring. The International Myeloma Working Group is set to revise its response criteria to incorporate these findings, potentially simplifying disease assessment and reducing the need for multiple blood draws.

In this episode of Better Edge, Northwestern Medicine Neurologist Shailee Shah, MD, and Neuro-oncologist Ditte Primdahl, MD, unpack the latest advancements in paraneoplastic syndrome management, highlighted at the 2025 American Academy of Neurology Annual Meeting.   Together, they explore: The complex interplay between immune checkpoint inhibitors and autoimmune neurologic syndromes Emerging therapies, including CD19-directed CAR T-cell treatments Updates to diagnostic criteria and risk stratification using high-risk autoantibodies The role of predictive biomarkers and advanced omics in diagnosis The launch of a dedicated paraneoplastic clinic at Northwestern Medicine

Recapping Season 8 Epsiodes 3 & 4 Amanda and Maggie are two silly ladies who have made plenty of silly mistakes. Amanda wins the mistake trophy for this season because she just completely skipped over an epsiodes and didn't edit or release it in time! HUGE shout out to listener (maybe their BFF?) Georgia for writing in to let them know she couldn't find this episode. So kind of her to call them in for their mistake while they shout it from the rooftops how thankful they are you let them know. Who knows how many thousands of you would have missed this little delight in your ears? Thanks, Georgia! (Also please leave a review if you haven't!):)  In this episode, the girls decide which one of Maggie's kids represents members of the firm, they have a very brief discussion about Star Trek, all while juggling a wild thunderstorm and Whisky the Producer Dog's reaction to all that noise.  For all things OSF, visit onlysuitsfans.com   

We start off with some good old spaceweather news, which leads into a discussion of the earth's rapidly weakening magnetic field and the possibility of a polarity flip. We then move on to some discussion of further observations on the construction of pyramids and new things we learned in our recent trip in Egypt. In the second half of the show, we talk about the amazing cart ruts we visited in the Phrygian Valley in Turkey. We show lots of pictures and video, and discuss and discard multiple hypotheses on what they are and how they were formed.   Join us, Ben from UnchartedX, Adam Young, and Karoly Poka for an afternoon at The Metropolitan Museum of Art in New York where we will peruse their collection of Ancient Egyptian artifacts, then we will move to the Explorer's Club for dinner and presentations from us and Ben! https://eveningattheexplorersclub.eventbrite.com/ Join our Patreon, support the show, get extra content and early access! https://www.patreon.com/brothersoftheserpent Support the show with a paypal donation: https://paypal.me/snakebros   Chapters 00:00 Welcome to Brothers of the Serpent 02:01 Space Weather News 05:32 Earth's Magnetic Field Dynamics 10:05 Geomagnetic Excursions and Their Implications 15:49 Magnetic Field Weakening and Its Consequences 20:08 Mars, Venus, and Planetary Magnetic Fields 24:22 Life on Other Planets: The Case of Europa 28:08 Life in Extreme Environments 29:51 Theoretical Life Forms and Energy 31:21 Science Fiction Inspirations 33:35 Podcast Reflections and Communication Barriers 34:35 Debating Ancient Structures 37:43 Pyramid Construction Insights 39:20 The Anatomy of Pyramids 42:30 Theories on Pyramid Design 50:30 Mythology and Historical Interpretation 58:24 Exploring the Met and Event Details 59:08 The Mystery of Cart Ruts 01:01:03 Colonial Cart Ruts: A Historical Perspective 01:03:20 Investigating Turkish Cart Ruts 01:06:03 Analyzing the Characteristics of Ruts 01:09:12 Theories on Rut Formation 01:12:32 Erosion and Its Impact on Ruts 01:15:58 The Case for Hand-Carved Ruts 01:19:20 Challenging Conventional Explanations 01:27:59 Concluding Thoughts on Cart Ruts 01:29:25 Exploring the Mechanics of Ruts 01:36:00 Drone Footage Insights 01:43:11 The Mystery of Disappearing Ruts 01:50:06 Theories and Speculations on Cart Ruts

These lectures will explore two Arthurian romances, Chretien de Troyes' Knight of the Cart, and the Cistercian text we know as The Quest of the Holy Grail, through the lens of Catholic teaching on redemption, divine grace, and the pursuit of virtue.

Episode 237 This episode has stories about lost items, telepathy, Korea, beverage carts, Sri Lanka and a backpack nazi. Contact... flywithbetty@gmail.com The Telepathy Tapes Ravens Cup Coffee and Art Gallery, La Conner, WA Let's Talk Off Camera My website Patreon Instagram:Bettyinthesky Twitter: Skybetty My Amazon page

This week's topics include treating hot flashes in breast cancer survivors, a blood test for detecting colorectal cancer, exercise to improve survival after colorectal cancer treatment and CAR-T therapy for solid tumors.Program notes:0:40 CAR-Ts for solid tumors1:40 Advanced gastric or gastroesophageal cancer2:40 Cytokine release syndrome3:22 Exercise after treatment for colorectal cancer4:23 Disease free survival superior5:23 Currently not much exercise6:23 Potential mechanisms7:10 Treating hot flashes in breast cancer survivors8:10 Neurokinin receptors9:12 A blood test to screen for colorectal cancer10:12 Asymptomatic adults11:12 Will not replace FIT or screening colonoscopy12:12 Survival advantage due to polypectomy13:19 End

Get a copy here: freeleaguepublishing.com/games/dragonbane/ Music Attribution: Theme: Black Vortex by Kevin McLeod Follow us!

 --www.TheatreMindPlay.com --FB: bit.ly/MindPlayersFB
 --Insta: bit.ly/MindPlayersIG
 --Twitter: bit.ly/MindPlayersTw 
--Twitch: bit.ly/MindplayersTwitch
 --YouTube: bit.ly/MindPlayersYT
 --Patreon: bit.ly/MindPlayersPat

Cart and Deion's post-NBA draft deadline top 10! Drafting the scariest college basketball coaches to recruit against! Drafting college basketball's most talented rosters! The Sleepers Podcast is now available daily with new episodes every Monday-Friday!

In this episode of The Influence Factor, Alessandro Bogliari speaks with Courtney Weis, Managing Director of Brand Marketing at FP Movement. Their conversation explores the brand's commitment to empowering women through activewear, the vital role of community involvement, and the dynamic shifts within influencer marketing. Courtney offers valuable perspectives on FP Movement's collaborations with athletes and creators, highlights the power of storytelling in brand marketing, and provides a preview of the brand's upcoming campaigns and activations.

This week we revisit Sherry Cola stepping straight out of the big screen into the Add to Cart universe. The “JOY RIDE” actress reflects on the importance of seeing Asian women fully represented as their wild, raunchy and hilarious selves. In the spirit of being true to yourself, Sherry dishes on her favorite Asian snacks and why her Hello Kitty subscription box is self-care. She also shares how she’s finding her zen, and why she’s removing from cart saying “yes” (but not to this podcast!) Please note, Add To Cart contains mature themes and may not be appropriate for all listeners. To see all products mentioned in this episode, head to @addtocartpod on Instagram. To purchase any of the products, see below. Sherry is healing her inner childhood with the Hello Kitty subscription box Her fave Asian snacks now are IRVINS Salted Egg Potato Chips Crisps and the classic wasabi peas ATC faves are Chingoo snacks and Loaf Language JOY RIDE is in theaters now! Randall Park’s movie Shortcomings (starring Sherry Cola) will be in theaters August 4 Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia. Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium. Click this link for a list of current sponsors and discount codes for this show and all Lemonada shows: lemonadamedia.com/sponsorsSee omnystudio.com/listener for privacy information.

This month, the gals are visited by Cassidy Liston from Drinking the Koolaid Podcast to discuss gull shrieking, mystery man meats, angel eggs, red-wing red flags, crystal-encrusted corpses, and a suspiciously bound book. Tune in for May's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.